Primaquine for Plasmodium vivax radical cure: What we do not know and why it matters

被引:8
|
作者
Popovici, Jean [1 ,2 ,3 ]
Tebben, Kieran [4 ]
Witkowski, Benoit [1 ,2 ,3 ]
Serre, David [4 ]
机构
[1] Inst Pasteur Cambodge, Malaria Mol Epidemiol Unit, Phnom Penh, Cambodia
[2] Inst Pasteur, Malaria Translat Res Unit, Paris, France
[3] Inst Pasteur Cambodge, Phnom Penh, Cambodia
[4] Univ Maryland, Sch Med, Inst Genome Sci, Baltimore, MD 21201 USA
关键词
MONOAMINE-OXIDASE; DRUG-METABOLISM; G6PD DEFICIENCY; MAO-A; MALARIA; ARTEMISININ; FALCIPARUM; POPULATION; RELAPSE; TAFENOQUINE;
D O I
10.1016/j.ijpddr.2020.12.004
中图分类号
R38 [医学寄生虫学]; Q [生物科学];
学科分类号
07 ; 0710 ; 09 ; 100103 ;
摘要
Plasmodium vivax radical cure requires the administration of a blood schizonticide for killing blood-stage parasites and the addition of a drug able to kill hypnozoites, the dormant parasite stages residing in the liver of infected patients. All drugs used clinically for killing hypnozoites are 8-aminoquinolines and among them, primaquine has been at the forefront of P. vivax case management for decades. We discuss here the possible factors that could lead to the emergence and selection of P. vivax primaquine resistant parasites and emphasize on how a better understanding of the mechanisms underlying primaquine treatment and hypnozoite biology is needed to prevent this catastrophic scenario from happening.
引用
收藏
页码:36 / 42
页数:7
相关论文
共 50 条